New Delhi, July 23 -- Imports of pharmaceutical raw materials worth Rs.1,362 crore were avoided by March 2025 due to domestic production of 25 identified items under the production-linked incentive (PLI) scheme for bulk drugs, the government informed Parliament on Tuesday.

In a written reply to the Rajya Sabha, Minister of State for Chemicals and Fertilisers Anupriya Patel said that as of March 2025, investments under the scheme had already exceeded the initial commitment.

This has helped establish domestic manufacturing capacity for 25 key starting materials (KSMs), drug intermediates (DIs), and active pharmaceutical ingredients (APIs), thereby significantly reducing import dependency.

Before the scheme's rollout, most of the products...